点击下方 关注我们
参考文献
1.LU L, SUO L, LI J, et al. A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China [J]. Hum Vaccin Immunother, 2018, 14(11): 2632-5.
2.TSAI TF, YAO CA, YU HS, et al. Herpes zoster-associated severity and duration of pain, health-related quality of life, and healthcare utilization in Taiwan: a prospective observational study [J]. Int J Dermatol, 2015, 54(5): 529-36.
3.Steinmann M, L.D., Grosser J, Schmidt J, Hohoff ML, Fischer A, Greiner W, Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and
heterogeneity patterns. Infection, 2024. 52(3): p. 1009-1026.
4.Muñoz-Quiles C, L.-L.M., Orrico-Sánchez A, Díez-Domingo J, Impact of postherpetic neuralgia: A six year population-based analysis on people aged 50 years or older. J Infect, 2018. 77: p. 131-136.
5.中国医师协会皮肤科医师分会带状疱疹专家共识工作组,国家皮肤与免疫疾病临床医学研究中心. 中国带状疱疹诊疗专家共识(2022版)[J]. 中华皮肤科杂志,2022,12:1033-1040.
6.MARRA F, PARHAR K, HUANG B, et al. Risk Factors for Herpes Zoster Infection: A Meta-Analysis [J]. Open Forum Infect Dis, 2020, 7(1): ofaa005.
7.Weinke T , Glogger A , Bertrand I ,et al.The Societal Impact of Herpes Zoster and Postherpetic Neuralgia on Patients, Life Partners, and Children of Patients in Germany[J].Scientificworldjournal, 2014.DOI:10.1155/2014/749698.
8.中国医疗保健国际交流促进会皮肤科分会. 带状疱疹疫苗预防接种专家共识[J]. 中华医学杂志,2022,102(8):538-543.
9.WHO, Guidelines on clinical evaluation of vaccines: regulatory expectations.
https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9.2020.
10.WHO, Vaccine efficacy, effectiveness and protection.
https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection.2021.
*腾讯医典内容团队出品
